Tinnitus. Tinnitus
Conditions
Interventions
Intervention 1: Intervention group underwent treatment with Neurotec capsule 100 mg twice daily for 3 months. Intervention 2: Control group patients underwent treatment with placebo twice daily for 3
Treatment - Drugs
Intervention group underwent treatment with Neurotec capsule 100 mg twice daily for 3 months
Control group patients underwent treatment with placebo twice daily for 3 months
Sponsors
Vice Chancellor for Research, Baqiyatallah University of Medical Sciences
Eligibility
Sex/Gender
All
Age
19 Years to 75 Years
Inclusion criteria
Inclusion criteria: Inclusion Criteria: 1- Informed consent 2- Tinnitus for at least 6 months 3- Age over 19 Exclusion criteria: 1-Pregnancy 2-Age over 75 and under 19 3-Chronic or Acute neurologic disease 4-Psychologic disease 5-Previous surgery on the affected ear 6-Pulsatile Tinnitus 7-Epilepsy 8-Multiple sclerosis 9- History of sever trauma to head and neck 10- History of treatment 1 month prior to intervention
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hearing Threshold. Timepoint: Before, one month and three months after interventin. Method of measurement: Pure Tone Audiometry.;Quality of Life. Timepoint: Before, one month and three months after interventin. Method of measurement: Tinnitus Handicap Inventory. | — |
Secondary
| Measure | Time frame |
|---|---|
| Drug Complications. Timepoint: During study. Method of measurement: Patients' complaint. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMohammad Hossein Khosravi
Student Research Committee, Baqiyatallah University of Medical Sciences, Tehran, Iran
Outcome results
None listed